Cervical HPV Infection
Conditions
Interventions
Experimental Group:Honghefu Jie lotion combined with Xinfuning
Control group:Honghefu Jie lotion placebo combined with Xinfuning
Sponsors
Changhai Hospital, Shanghai, China
Eligibility
Sex/Gender
Female
Age
21 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) aged 21-65 years, non-pregnant, non-lactating, and having a history of sexual life; 2) diagnosed as uterine by any of the methods of HC2 test, HPV genotyping surveillance, or PCR Positive cervical high-risk human papillomavirus infection; 3) downpour type with dampness and heat; 4) no recent fertility requirements; 5) Thinprep cytology test (TCT) : NILM, inflammatory changes; 6) patients who voluntarily participated in the clinical trial and actively cooperated with follow-up and signed informed consent
Exclusion criteria
Exclusion criteria: 1) Thinprep cytologic test (TCT) for high-grade squamous intraepithelial lesions and invasive carcinoma;Patients with high-grade CIN II and above lesions by histopathology; 2) use of other HPV drugs or immunosuppressive drugs in the three months before enrollment; 3) pregnant and lactating women; 4) combined with mental disorders, or with important organ diseases or metabolic diseases; 5) combined with infectious diseases, such as tuberculosis, venereal diseases; 6) those with bad habits or recent exposure to toxic substances, such as drugs and X-rays; 7) are receiving additional clinical trial investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cervical HPV testing; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cervical liquid-based cytology; | — |
Countries
China
Contacts
Public ContactYu Chaoqin
Changhai Hospital, Shanghai, China
Outcome results
None listed